淋巴细胞CD44在早期非小细胞肺癌立体定向体部放疗与手术选择中的潜在作用
该研究利用空间蛋白质组学分析44例一线接受立体定向体部放疗(SBRT)的早期非小细胞肺癌(ES-NSCLC)活检组织,发现淋巴细胞区CD44高表达与更差的无复发生存(RFS)和更高复发率相关,并在52例SBRT和62例手术患者中验证;CD44低表达者SBRT的RFS优于手术,而CD44高表达者手术优于SBRT。
要点
- 淋巴细胞区CD44高表达与SBRT后更差RFS和更高复发率相关。
- CD44低表达患者SBRT的RFS显著优于手术,CD44高表达患者手术优于SBRT。
- 淋巴细胞CD44或可作为SBRT疗效预测及SBRT与手术选择的生物标志物,尚待大样本前瞻性数据验证。
核心结论
- 淋巴细胞CD44可能不仅是该人群SBRT疗效的预测因子,也是可能改善ES-NSCLC中SBRT与手术选择的重要生物标志物,尚待大样本前瞻性数据验证。
研究设计与样本
- 研究纳入44例接受一线SBRT的ES-NSCLC患者活检组织作为队列1,用GeoMx数字空间分析(DSP)检测5个空间分子区室中70种蛋白。
- 队列2纳入52例接受SBRT的ES-NSCLC患者活检样本,队列3纳入62例接受手术的ES-NSCLC患者活检样本,均用多重免疫荧光(mIF)分析以验证队列1发现。
主要发现
- 队列1中,淋巴细胞区室CD44表达较高与较差的无复发生存(RFS)相关(DSP:P < .001;mIF:P < .001),并与较高复发率相关(DSP:P = .001;mIF:P = .004)。
- 队列2的mIF数据验证了上述发现(所有P < .05)。
- 队列3中,淋巴细胞CD44较高预测手术后较高RFS(P = .003)。
- 跨模式比较显示,在CD44低表达患者中SBRT的RFS显著高于手术(P < .001),而在CD44高表达病例中手术优于SBRT(P = .016)。
临床怎么用
- 原文未据此给出推荐。
- 作者认为淋巴细胞CD44可能作为预测SBRT疗效及辅助SBRT与手术选择的生物标志物,尚待大样本前瞻性数据验证。
局限性
- 原文结论指出淋巴细胞CD44作为生物标志物尚待大样本前瞻性数据验证(pending validation by large prospective data)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic body radiation therapy (SBRT) versus surgery for operable early-stage non-small cell lung cancer (ES-NSCLC) remains highly debated. Herein, we used spatial proteomics to identify whether any molecular biomarker(s) associate with the efficacy of either modality, in efforts to optimize treatment selection between surgery and SBRT for this population. METHODS AND MATERIALS: We evaluated biopsy tissue samples from 44 patients with ES-NSCLC treated with first-line SBRT (cohort 1) by GeoMx Digital Spatial Profiling (DSP) with a panel of 70 proteins in 5 spatial molecular compartments: tumor (panCK+), leukocyte (CD45+), lymphocyte (CD3+), macrophage (CD68+), and stroma (α-SMA+). To validate the findings in cohort 1, biopsy samples from 52 patients with ES-NSCLC who received SBRT (cohort 2) and 62 patients with ES-NSCLC who underwent surgery (cohort 3) were collected and analyzed by multiplex immunofluorescence (mIF). RESULTS: In cohort 1, higher CD44 expression in the lymphocyte compartment was associated with poorer recurrence-free survival (RFS) (DSP: P < .001; mIF: P < .001) and higher recurrence rate (DSP: P = .001; mIF: P = .004). mIF data from cohort 2 validated these findings (P < .05 for all). From cohort 3, higher lymphocyte CD44 predicted higher RFS after surgery (P = .003). Intermodality comparisons demonstrated that SBRT was associated with significantly higher RFS over surgery in CD44-low patients (P < .001), but surgery was superior to SBRT in CD44-high cases (P = .016). CONCLUSIONS: Lymphocyte CD44 may not only be a predictor of SBRT efficacy in this population but also an important biomarker (pending validation by large prospective data) that could better sharpen selection for SBRT versus surgery in ES-NSCLC.
引用
- Yan W, Ren Z, Chen X, et al. Potential Role of Lymphocyte CD44 in Determining Treatment Selection Between Stereotactic Body Radiation Therapy and Surgery for Early-Stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2024. PMID: 38447611. doi:10.1016/j.ijrobp.2024.02.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。